Uniqure (NASDAQ:QURE) has been assigned a $35.00 price objective by equities research analysts at HC Wainwright in a note issued to investors on Thursday, March 15th. The firm presently has a “buy” rating on the biotechnology company’s stock. HC Wainwright’s price objective would suggest a potential upside of 59.38% from the stock’s current price.
A number of other equities analysts have also recently weighed in on the stock. Zacks Investment Research cut shares of Uniqure from a “hold” rating to a “sell” rating in a research report on Saturday, February 24th. Janney Montgomery Scott began coverage on shares of Uniqure in a research report on Wednesday, January 3rd. They issued a “buy” rating and a $25.00 target price for the company. BidaskClub upgraded shares of Uniqure from a “hold” rating to a “buy” rating in a research report on Wednesday, December 27th. Finally, ValuEngine upgraded shares of Uniqure from a “sell” rating to a “hold” rating in a research report on Tuesday, December 26th. Four equities research analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. The stock has a consensus rating of “Buy” and a consensus target price of $21.38.
NASDAQ QURE traded down $0.60 during mid-day trading on Thursday, reaching $21.96. 227,113 shares of the stock were exchanged, compared to its average volume of 341,390. The company has a debt-to-equity ratio of 0.22, a quick ratio of 8.46 and a current ratio of 8.46. The company has a market capitalization of $695.78, a PE ratio of -7.47 and a beta of 0.18. Uniqure has a 1 year low of $4.72 and a 1 year high of $27.19.
Uniqure (NASDAQ:QURE) last posted its quarterly earnings data on Wednesday, March 14th. The biotechnology company reported ($0.91) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.68) by ($0.23). The company had revenue of $2.58 million for the quarter, compared to analyst estimates of $2.83 million. Uniqure had a negative return on equity of 174.25% and a negative net margin of 604.72%. equities analysts expect that Uniqure will post -3.21 EPS for the current year.
In other news, CEO Matthew C. Kapusta sold 39,169 shares of the firm’s stock in a transaction that occurred on Thursday, March 15th. The shares were sold at an average price of $21.72, for a total value of $850,750.68. Following the completion of the transaction, the chief executive officer now owns 439,764 shares of the company’s stock, valued at $9,551,674.08. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, insider Deventer Sander Van sold 5,985 shares of the firm’s stock in a transaction that occurred on Monday, January 29th. The shares were sold at an average price of $18.53, for a total transaction of $110,902.05. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 48,032 shares of company stock valued at $1,014,982. 0.73% of the stock is currently owned by insiders.
Hedge funds and other institutional investors have recently bought and sold shares of the company. OxFORD Asset Management LLP purchased a new position in shares of Uniqure in the third quarter valued at approximately $399,000. Opaleye Management Inc. acquired a new position in shares of Uniqure in the 4th quarter valued at $1,778,000. Royce & Associates LP acquired a new position in shares of Uniqure in the 4th quarter valued at $2,449,000. Victory Capital Management Inc. acquired a new position in shares of Uniqure in the 4th quarter valued at $1,298,000. Finally, Tekla Capital Management LLC increased its holdings in shares of Uniqure by 38.1% in the 4th quarter. Tekla Capital Management LLC now owns 332,850 shares of the biotechnology company’s stock valued at $6,521,000 after acquiring an additional 91,829 shares during the period. 42.76% of the stock is owned by institutional investors and hedge funds.
TRADEMARK VIOLATION WARNING: This piece was originally reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this piece on another site, it was illegally stolen and republished in violation of US and international trademark and copyright laws. The original version of this piece can be read at https://www.dispatchtribunal.com/2018/04/08/uniqure-qure-given-a-35-00-price-target-by-hc-wainwright-analysts.html.
Uniqure Company Profile
uniQure N.V., a biopharmaceutical company, engages in the discovery, development, and commercialization of gene therapies in the Netherlands. The company's principle programs include AMT-060, a gene therapy that has completed Phase I/II clinical trial for the treatment of hemophilia B; S100A1, a preclinical product candidate for the treatment of congestive heart failure; and AMT-130 for the treatment of huntington's disease.
Receive News & Ratings for Uniqure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Uniqure and related companies with MarketBeat.com's FREE daily email newsletter.